文献速递类风湿关节炎脊柱关节炎

屏蔽措施降低炎症性关节炎患者COVID-19发病率但脆弱性与死亡率增加相关

Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该回顾性人群队列研究利用威尔士SAIL数据库数据,纳入2020年3月至2021年5月COVID-19检测阳性的炎症性关节炎(IA)患者1966例及无IA者166602例。IA患者COVID-19发病率为3.5%(1966/56914),普通人群为6%(166602/2760442),差异2.5%(95%CI:2.4%,2.7%,P≤0.001)。校正Cox模型显示IA与死亡率升高无关(HR:0.56,95%CI:0.18,1.64,P=0.286),而屏蔽状态、既往感染住院、大流行前一年住院及糖皮质激素使用与死亡风险升高相关。

要点

  • IA患者COVID-19发病率3.5%低于普通人群6%,差异2.5%(95%CI:2.4%,2.7%,P≤0.001),可能归因于屏蔽。
  • 校正后IA与COVID-19后死亡率升高无关(HR:0.56,95%CI:0.18,1.64,P=0.286)。
  • 屏蔽(HR:1.52)、既往感染住院(HR:1.20)、大流行前一年住院(HR:1.34)及糖皮质激素使用(HR:1.17)与死亡风险升高相关。

核心结论

  • IA患者COVID-19发病率较低,可能归因于屏蔽;IA与COVID-19感染后死亡率升高无关,而脆弱性(被屏蔽)、合并症及其他因素与风险增加相关。
  • 这些关键风险因素可识别COVID-19风险较高的IA患者,并建议在高社区流行期间进行屏蔽。

研究设计与样本

  • 回顾性、基于人群的队列研究,使用SAIL Databank链接的匿名电子健康数据,涵盖初级/二级保健、风湿病学、国家统计局死亡及COVID-19实验室数据。
  • 研究对象为2020年3月至2021年5月期间COVID-19检测阳性、年龄18岁及以上、具有类风湿关节炎、银屑病关节炎和强直性脊柱炎READ编码的个体。

主要发现

  • IA患者1966例与无IA者166602例COVID-19检测阳性。
  • IA患者COVID-19发病率为3.5%(1966/56914),普通人群为6%(166602/2760442),差异2.5%(95%CI:2.4%,2.7%,P≤0.001)。
  • 校正Cox比例风险模型中,IA与死亡率升高无关(HR:0.56,95%CI:0.18,1.64,P=0.286)。
  • 显著风险因素包括屏蔽(HR:1.52,95%CI:1.40,1.64,P≤0.001)、既往感染住院(HR:1.20,95%CI:1.12,1.28,P≤0.001)、大流行前一年住院(HR:1.34,95%CI:1.25,1.44,P≤0.001)及糖皮质激素使用(HR:1.17,95%CI:1.09,1.25,P≤0.001)。

关键数值与推荐

  • IA患者COVID-19发病率3.5%(1966/56914) vs 普通人群6%(166602/2760442),差异2.5%(95%CI:2.4%,2.7%,P≤0.001)。
  • IA与死亡率关联的校正HR为0.56(95%CI:0.18,1.64,P=0.286)。
  • 屏蔽的HR为1.52(95%CI:1.40,1.64,P≤0.001);既往感染住院的HR为1.20(95%CI:1.12,1.28,P≤0.001);大流行前一年住院的HR为1.34(95%CI:1.25,1.44,P≤0.001);糖皮质激素使用的HR为1.17(95%CI:1.09,1.25,P≤0.001)。

临床怎么用

  • 作者指出这些关键风险因素可识别COVID-19风险较高的IA患者,并建议在高社区流行期间进行屏蔽。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Investigate whether individuals with inflammatory arthritis (IA), their treatments and shielding status affect the risk of adverse outcomes from COVID-19 for the entire population of Wales, UK. METHODS: Retrospective, population-based cohort study using linked, anonymized electronic health data from SAIL Databank, including primary/secondary care, rheumatology, Office for National Statistics Mortality and COVID-19 laboratory data. Individuals aged 18 years and over testing positive for COVID-19 between March 2020 and May 2021 with READ Codes present for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis formed the study cases. RESULTS: A total of 1966 people with IA and 166 602 without tested positive for COVID-19. The incidence rate was 3.5% (1966/56 914) in IA, vs 6% in the general population (166 602/2 760 442), (difference: 2.5%, 95% CI: 2.4%, 2.7%, P ≤0.001). In an adjusted Cox proportional hazard model, IA was not associated with higher mortality (HR: 0.56, 95% CI: 0.18, 1.64, P=0.286). Significant risk factors included shielding (HR: 1.52, 95% CI: 1.40, 1.64, P ≤0.001), hospitalization for previous infections (HR: 1.20, 95% CI: 1.12, 1.28, P ≤0.001), hospitalizations one year pre-pandemic (HR: 1.34, 95% CI: 1.25, 1.44, P ≤0.001) and glucocorticoid use (HR: 1.17, 95% CI: 1.09, 1.25, P ≤0.001). CONCLUSIONS: Individuals with IA had a lower incidence of COVID-19, probably due to shielding. IA was not associated with increased mortality following COVID-19 infection; being vulnerable (shielded), comorbidities and other factors were associated with increased risk. These key risk factors can identify individuals with IA at greater risk from COVID-19 and advised to shield during high community prevalence.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cooksey R, Underwood J, Brophy S, et al. Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality. Rheumatology (Oxford). 2022. PMID: 35567479. doi:10.1093/rheumatology/keac283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。